Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)
Status:
Withdrawn
Trial end date:
2020-06-29
Target enrollment:
Participant gender:
Summary
There is no known definite treatment after exposure to SARS-CoV-2, but the some animal and
clinical trials confirmed the efficacy of hydroxychloroquine (HCQ) or chloroquine against
SARS-CoV-2. Thus, in this study, we aim to evaluate the efficacy and safety of
hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2.
- Primary end point: comparison the rate of COVID-19 between PEP with HCQ and control
group.
- Secondary end point: Comparison of the rate of COVID-19 according to the contact level
(time, place, degree of wearing personal protective equipment).
- Safety comparison: Safety verification by identifying major side effects in the HCQ
group."